Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation

被引:31
|
作者
Taha, Maie S. [1 ,2 ,3 ]
Padmakumar, Smrithi [1 ]
Singh, Amit [4 ]
Amiji, Mansoor M. [1 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, 360 Huntington Ave, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Eye & Ear Infirmary, 243 Charles St, Boston, MA 02114 USA
[3] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt
[4] Puretech Hlth, 6 Tide St, Boston, MA 02210 USA
关键词
Nanomedicine; Clinical translation; Drug delivery; Challenges; Nanoparticles; Quality attributes; Quality-by-design (QbD); NANOPARTICLE SURFACE-CHARGE; DRUG-DELIVERY SYSTEMS; PROTEIN CORONA; POLYMERIC NANOPARTICLES; DESIGN APPROACH; HYBRID NANOPARTICLES; LIPID NANOPARTICLES; IN-VITRO; PHYSICOCHEMICAL PROPERTIES; INORGANIC NANOPARTICLES;
D O I
10.1007/s13346-020-00744-1
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
Nanomedicine is a rapidly emerging field with several breakthroughs in the therapeutic drug delivery application. The unique properties of the nanoscale delivery systems offer huge advantages to their payload such as solubilization, increased bioavailability, and improved pharmacokinetics with an overall goal of enhanced therapeutic index. Nanomedicine has the potential for integrating and enabling new therapeutic modalities. Several nanoparticle-based drug delivery systems have been granted approval for clinical use based on their outstanding clinical outcomes. Nanomedicine faces several challenges that hinder the realization of its full potential. In this review, we discuss the critical formulation- and biological-related quality features that significantly influence the performance of nanoparticulate systems in vivo. We also discuss the quality-by-design approach in the pharmaceutical manufacturing and its implementation in the nanomedicine. A deep understanding of these nanomedicine quality checkpoints and a systematic design that takes them into consideration will hopefully expedite the clinical translation process. Graphical abstract
引用
收藏
页码:766 / 790
页数:25
相关论文
共 50 条
  • [1] Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation
    Maie S. Taha
    Smrithi Padmakumar
    Amit Singh
    Mansoor M. Amiji
    Drug Delivery and Translational Research, 2020, 10 : 766 - 790
  • [2] Clinical translation of nanomedicines
    Svenson, Sonke
    CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE, 2012, 16 (06): : 287 - 294
  • [3] Current developments and applications of microfluidic technology toward clinical translation of nanomedicines
    Liu, Dongfei
    Zhang, Hongbo
    Fontana, Flavia
    Hirvonen, Jouni T.
    Santos, Helder A.
    ADVANCED DRUG DELIVERY REVIEWS, 2018, 128 : 54 - 83
  • [4] Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes
    Dri, Diego Alejandro
    Rinaldi, Federica
    Carafa, Maria
    Marianecci, Carlotta
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2023, 13 (03) : 757 - 769
  • [5] Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes
    Diego Alejandro Dri
    Federica Rinaldi
    Maria Carafa
    Carlotta Marianecci
    Drug Delivery and Translational Research, 2023, 13 : 757 - 769
  • [6] Fc glycans of therapeutic antibodies as critical quality attributes
    Reusch, Dietmar
    Tejada, Max L.
    GLYCOBIOLOGY, 2015, 25 (12) : 1325 - 1334
  • [7] Fundamentals of nanomedicines towards clinical translation
    Sarmento, Bruno
    Little, Steve
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2020, 10 (03) : 571 - 571
  • [8] Critical Quality Attributes for Supply of Clinical Plasmids for Cell and Gene Therapy Development
    Thiaville, Patrick
    MOLECULAR THERAPY, 2022, 30 (04) : 532 - 532
  • [9] Fundamentals of nanomedicines towards clinical translation
    Bruno Sarmento
    Steve Little
    Drug Delivery and Translational Research, 2020, 10 : 571 - 571
  • [10] Critical quality attributes challenge biologics development
    Haigney, Susan
    Pharmaceutical Technology, 2017, 41 (04) : 50 - 51